DRTSW Company Profile and Key Details

Alpha Tau Medical Ltd. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 10, 2026, missed forecasts by 254.91%. The prior quarter beat by 110.42%. Over the last six quarters, Apple has recorded several small beats. These include -2.06% in May 19, 2025.

DRTSW has shown weak momentum, losing -10.0% over the past week and -10.03% over the past quarter, though year-to-date performance is down -10.03%. Average 10-day trading volume of 54.43 thousand shares is below the 3-month average of 70.34 thousand, indicating normal recent market interest.

Alpha Tau Medical Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.03. This means the shares are trading above this model’s fair value.

Alpha Tau Medical Ltd. (NASDAQ:DRTSW) closed at $3.72 USD, losing -$0.05 (-1.33%) from the previous close of $3.77. The stock is currently within 5% of its 52-week high $0.33 and $3.88. With a market capitalization of about $1.44 billion, Alpha Tau Medical Ltd. is classified as a small-cap and shows market-like volatility (beta ~1.19). Key stats such as the average daily volume over the past year has been around 71.76 thousand shares, volume is running light vs its 52-week average. Headquartered in Jerusalem, JM, Alpha Tau Medical Ltd. operates in the Healthcare sector and the Medical - Equipment & Services industry. Led by CEO Uzi Sofer, the company employs approximately 112 people and listed since March 06, 2026. Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer.

Alpha Tau Medical Ltd. trades at a P/E ratio of -13.78, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 29.6 reflecting a rich premium to book value. The P/FCF stands at -39.53, also below market averages. Compared to sector medians, Alpha Tau Medical Ltd. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Alpha Tau Medical Ltd. (NASDAQ:DRTSW) shares are down -10.03% year-to-date Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Alpha Tau Medical Ltd. trading at a premium to the broader market with a P/E of -13.78.

Our AI price prediction model suggests that Alpha Tau Medical Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -93.37%, with price expected at $0.25 by November 24, 2023, within a range of $0.23 to $0.27